HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index

被引：0

作者：

Hatanaka, K. ^{[1
]}

Yuki, S. ^{[2
]}

Nakano, S. ^{[2
]}

Sawada, K. ^{[3
]}

Harada, K. ^{[4
]}

Okuda, H. ^{[5
]}

Ando, T. ^{[6
]}

Ogawa, K. ^{[7
]}

Furukawa, K. ^{[8
]}

Minami, S. ^{[9
]}

Saiki, T. ^{[10
]}

Ohta, T. ^{[11
]}

Kato, T. ^{[12
]}

Nakajima, J. ^{[13
]}

Sasaki, T. ^{[14
]}

Saitoh, S. ^{[15
]}

Shindo, Y. ^{[16
]}

Tateyama, M. ^{[17
]}

Kato, S. ^{[18
]}

Nagai, H. ^{[19
]}

Sakata, Y. ^{[20
]}

Komatsu, Y. ^{[21
]}

机构：

[1] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan

[2] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Hokkaido, Japan

[4] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Hokkaido, Japan

[5] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[6] Univ Toyama, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan

[7] Kouseiren Takaoka Hosp, Dept Gastroenterol, Takaoka, Toyama, Japan

[8] Niigata City Gen Hosp, Dept Gastroenterol, Niigata, Japan

[9] Oji Gen Hosp, Dept Gastroenterol, Tomakomai, Japan

[10] Teine Keijinkai Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[11] Sapporo Higashi Tokushukai Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[12] Wakkanai City Hosp, Dept Internal Med, Wakkanai, Hokkaido, Japan

[13] Obihiro Kosei Hosp, Dept Gastroenterol, Obihiro, Hokkaido, Japan

[14] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[15] Misawa City Hosp, Dept Internal Med, Misawa, Japan

[16] Nakadori Gen Hosp, Dept Surg Gastroenterol, Akita, Japan

[17] Tomakomai Nisshou Hosp, Dept Internal Med, Tomakomai, Japan

[18] Sapporo Hokuyu Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[19] HGCSG, Data Ctr, Sapporo, Hokkaido, Japan

[20] Misawa City Hosp, Misawa, Japan

[21] Hokkaido Univ Hosp, Div Canc Ctr, Digest Internal Med, Sapporo, Hokkaido, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P - 261

引用

页数：1

共 50 条

[31] Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
Fujii, Hironori
Matsuhashi, Nobuhisa
Kitahora, Mika
Takahashi, Takao
Hirose, Chiemi
Iihara, Hirotoshi
Yamada, Yunami
Watanabe, Daichi
Ishihara, Takuma
Suzuki, Akio
Yoshida, Kazuhiro
ONCOLOGIST, 2020, 25 (03): : E469 - E476
[32] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Johanna C. Bendell
Lee S. Rosen
Robert J. Mayer
Jonathan W. Goldman
Jeffrey R. Infante
Fabio Benedetti
Donghu Lin
Hirokazu Mizuguchi
Christopher Zergebel
Manish R. Patel
Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
[33] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Bendell, Johanna C.
Rosen, Lee S.
Mayer, Robert J.
Goldman, Jonathan W.
Infante, Jeffrey R.
Benedetti, Fabio
Lin, Donghu
Mizuguchi, Hirokazu
Zergebel, Christopher
Patel, Manish R.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
[34] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
Kotani, D.
Kuboki, Y.
Yasuda, K.
Nakamura, Y.
Kawazoe, A.
Bando, H.
Taniguchi, H.
Shitara, K.
Yoshino, T.
ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
[35] TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study
Yoshino, Takayuki
Uetake, Hiroyuki
Fujita, Naohiro
Furuta, Takaaki
Katori, Jun
Hara, Naoko
Muro, Kei
CLINICAL COLORECTAL CANCER, 2016, 15 (04) : E205 - E211
[36] Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis.
Abrahao, Ana Beatriz Kinupe
Ko, Yoo-Joung
Chan, Kelvin K.
Berry, Scott R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[37] Retrospective cohort study on the safety and efficacy of cetuximab for metastatic colorectal cancer patients: HGCSG0901-Analysis of predictive markers.
Hatanaka, Kazuteru
Yuki, Satoshi
Nakatsumi, Hiroshi
Kogawa, Takahiro
Fukushima, Hiraku
Fujikawa, Koshi
Sato, Yasushi
Saito, Mayuko
Munakata, Masaki
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[38] A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Chen, Xiaochen
Qiu, Huafeng
Chen, Yunwang
Wang, Mingxing
Zhu, Pengfei
Pan, Shuangyue
Deng, Yaya
Yang, Liu
Chen, Zheling
FRONTIERS IN ONCOLOGY, 2021, 11
[39] Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study-Analysis of adverse events
Dazai, Masayoshi
Fukushima, Hiraku
Sato, Yasushi
Yuki, Satoshi
Ohnuma, Hiroyuki
Okuda, Hiroyuki
Tsuji, Yasushi
Kawamoto, Yasuyuki
Hatanaka, Kazuteru
Iwanaga, Ichiro
Koike, Masahiko
Kato, Takashi
Nakamura, Michio
Sogabe, Susumu
Fujikawa, Koshi
Hosokawa, Ayumu
Hisai, Hiroyuki
Tateyama, Miki
Sakata, Yuh
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[40] A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.
Masuishi, Toshiki
Taniguchi, Hiroya
Hamauchi, Satoshi
Komori, Azusa
Kito, Yosuke
Mitani, Seiichiro
Hasegawa, Hiroko
Narita, Yukiya
Kadowaki, Shigenori
Ura, Takashi
Ando, Masashi
Mori, Keita
Tajika, Masahiro
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)

← 1 2 3 4 5 →